AEGLEA
Dead / Abandoned — Abandoned — no statement of use filed (as of 03 Jun 2024)
What this means for you
This application is over — abandoned 03 Jun 2024. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 90138790
- Mark type
- Stylized text
- Filed
- 26 Aug 2020
- Published for opposition
- 07 Sept 2021
- Abandoned
- 03 Jun 2024
- Attorney of record
- Christopher M. Kindel
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of rare genetic diseases; pharmaceutical preparations for the treatment of Arginase 1 deficiency; pharmaceutical preparations for the treatment of cancer; biopharmaceutical preparations for the treatment of rare genetic diseases; biopharmaceutical preparations for the treatment of Arginase 1 deficiency; biopharmaceutical preparations for the treatment of cancer; biotherapeutic preparations for the treatment of rare genetic diseases; biotherapeutic preparations for the treatment of Arginase 1 deficiency; biotherapeutic preparations for the treatment of cancer; biotherapeutic preparations and substances for the treatment of rare genetic diseases; biotherapeutic preparations and substances for the treatment of Arginase 1 deficiency; biotherapeutic preparations and substances for the treatment of cancer; enzyme replacement therapy preparations for medical purposes; pharmaceutical preparations for the prevention and treatment of infectious diseases and immunological diseases; biopharmaceutical preparations for the prevention and treatment of infectious diseases and immunological diseases; pharmaceutical preparations for the treatment of homocystinuria; biopharmaceutical preparations for the treatment of homocystinuria; biotherapeutic preparations for the treatment of homocystinuria
- Class 042 — Scientific and technological services: Scientific research in the fields of pharmaceuticals, biopharmaceuticals, medicine, biologics, biotherapeutics, biosimilars, enzyme replacement therapeutics, and therapeutics, all for the treatment of rare genetic diseases, Arginase 1 deficiency, cancer, immunological diseases, homocystinuria, and infectious diseases; medical and scientific research in the field of pharmaceutical and biopharmaceutical treatment of rare genetic diseases, Arginase 1 deficiency, cancer, immunological diseases, homocystinuria, and infectious diseases; providing medical and scientific research information, consultancy, and advisory services, all in the fields of pharmaceuticals, biopharmaceuticals, medicine, biologics, biotherapeutics, biosimilars, enzyme replacement therapeutics, and therapeutics treatments, and all for the treatment of rare genetic diseases, Arginase 1 deficiency, cancer, immunological diseases, homocystinuria, and infectious diseases; Design, engineering, research, development and testing services, all for medical research purposes in the fields of cancer, rare genetic disease, Arginase 1 deficiency treatments, immunological diseases, homocystinuria, and infectious diseases
Owner
- Aeglea BioTherapeutics, Inc., Austin, TX, US
- Aeglea BioTherapeutics, Inc., Austin, TX, US
Prosecution history
- 12 Jul 2024 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 03 Jun 2024 — ABANDONMENT - NO USE STATEMENT FILED
- 16 May 2024 — ASSIGNED TO EXAMINER
- 04 Nov 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 02 Nov 2023 — SOU EXTENSION 4 GRANTED
- 02 Nov 2023 — SOU EXTENSION 4 FILED
- 02 Nov 2023 — SOU TEAS EXTENSION RECEIVED
- 03 May 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 01 May 2023 — SOU EXTENSION 3 GRANTED
- 01 May 2023 — SOU EXTENSION 3 FILED
- 01 May 2023 — SOU TEAS EXTENSION RECEIVED
- 03 Nov 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 01 Nov 2022 — SOU EXTENSION 2 GRANTED
- 01 Nov 2022 — SOU EXTENSION 2 FILED
- 01 Nov 2022 — SOU TEAS EXTENSION RECEIVED